PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Deepika Jalota Sells 33,065 Shares

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) insider Deepika Jalota sold 33,065 shares of the firm’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total value of $35,048.90. Following the completion of the transaction, the insider owned 89,959 shares in the company, valued at $95,356.54. This represents a 26.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

PMV Pharmaceuticals Stock Performance

Shares of NASDAQ PMVP opened at $1.21 on Friday. PMV Pharmaceuticals, Inc. has a 52-week low of $0.81 and a 52-week high of $1.82. The stock has a market cap of $62.86 million, a P/E ratio of -1.03 and a beta of 1.49. The firm has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.19.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. Analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of PMV Pharmaceuticals in a research note on Thursday, March 20th.

Institutional Trading of PMV Pharmaceuticals

A number of institutional investors have recently modified their holdings of PMVP. BML Capital Management LLC lifted its stake in PMV Pharmaceuticals by 8.1% in the 1st quarter. BML Capital Management LLC now owns 3,747,612 shares of the company’s stock valued at $4,085,000 after acquiring an additional 280,928 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of PMV Pharmaceuticals by 17.6% in the first quarter. Stonepine Capital Management LLC now owns 630,183 shares of the company’s stock valued at $687,000 after purchasing an additional 94,378 shares during the last quarter. Aldebaran Capital LLC increased its stake in PMV Pharmaceuticals by 4.3% in the 1st quarter. Aldebaran Capital LLC now owns 523,553 shares of the company’s stock valued at $571,000 after buying an additional 21,363 shares during the last quarter. Two Sigma Investments LP raised its stake in shares of PMV Pharmaceuticals by 5.0% during the 4th quarter. Two Sigma Investments LP now owns 506,986 shares of the company’s stock worth $766,000 after purchasing an additional 23,931 shares in the last quarter. Finally, Peapod Lane Capital LLC grew its stake in shares of PMV Pharmaceuticals by 9.8% in the first quarter. Peapod Lane Capital LLC now owns 489,370 shares of the company’s stock valued at $533,000 after buying an additional 43,626 shares in the last quarter. 90.20% of the stock is currently owned by institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.